We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

230 hedge funds and large institutions have $1.64B invested in Supernus Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 101 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

34% more call options, than puts

Call options by funds: $5.37M | Put options by funds: $4M

3% more capital invested

Capital invested by funds: $1.59B → $1.64B (+$52.8M)

3% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 33

2% less funds holding

Funds holding: 235 → 230 (-5)

2.66% less ownership

Funds ownership: 103.85% → 101.19% (-2.7%)

33% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 101

Holders
230
Holders Change
-5
Holders Change %
-2.13%
% of All Funds
3.63%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
32
Increased
68
Reduced
101
Closed
33
Calls
$5.37M
Puts
$4M
Net Calls
+$1.37M
Net Calls Change
+$2.48M

Top Buyers

1
WP
Woodline Partners
California
+$14.9M
2
BlackRock
BlackRock
New York
+$13.4M
3
Goldman Sachs
Goldman Sachs
New York
+$8.76M
4
SCM
Soleus Capital Management
Connecticut
+$7.7M
5
PCH
Polar Capital Holdings
United Kingdom
+$7.66M

Top Sellers

1
AC
Armistice Capital
New York
-$31.8M
2
GT
Glenmede Trust
Pennsylvania
-$8.18M
3
N
Nuveen
North Carolina
-$7.43M
4
BGIM
Brandywine Global Investment Management
Pennsylvania
-$6.6M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$287M +$13.4M +438,553 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$179M +$787K +25,671 +0.5%
AC
3
Armistice Capital
New York
$100M -$31.8M -1,036,000 -25%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$71.8M -$592K -19,301 -0.9%
State Street
5
State Street
Massachusetts
$59.6M +$1.88M +61,282 +3%
GKIM
6
GW&K Investment Management
Massachusetts
$59.1M -$287K -9,375 -0.5%
Loomis, Sayles & Company
7
Loomis, Sayles & Company
Massachusetts
$52.7M -$1.27M -41,554 -2%
SIMG
8
Stephens Investment Management Group
Texas
$51.8M +$716K +23,364 +1%
ACB
9
Aristotle Capital Boston
Massachusetts
$40.7M -$852K -27,805 -2%
Renaissance Technologies
10
Renaissance Technologies
New York
$40.2M +$135K +4,400 +0.4%
ACM
11
Ashford Capital Management
Delaware
$36.3M +$2.11M +68,875 +7%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$30.1M -$972K -31,701 -3%
RHJA
13
Rice Hall James & Associates
California
$27.6M -$58.4K -1,906 -0.2%
Ameriprise
14
Ameriprise
Minnesota
$27.4M +$674K +21,987 +3%
Victory Capital Management
15
Victory Capital Management
Texas
$26.9M -$234K -7,641 -0.9%
FCM
16
Frontier Capital Management
Massachusetts
$21.1M +$1.03M +33,654 +5%
Northern Trust
17
Northern Trust
Illinois
$20.3M -$765K -24,958 -4%
Invesco
18
Invesco
Georgia
$20.1M -$3.79M -123,486 -17%
Goldman Sachs
19
Goldman Sachs
New York
$17.8M +$8.76M +285,737 +108%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$17.6M -$38.4K -1,251 -0.2%
IBT
21
International Biotechnology Trust
United Kingdom
$17.5M – – –
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$16.7M -$21.3K -694 -0.1%
Bank of America
23
Bank of America
North Carolina
$16.3M -$943K -30,746 -6%
N
24
Nuveen
North Carolina
$16M -$7.43M -242,239 -32%
EIP
25
Epoch Investment Partners
New York
$16M +$1.13M +36,960 +8%
1
2 3 4 5

SUPN Hedge Fund Activity: Q1 2022 in Review

230 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2022, worth a combined $1.64B — up 3.3% from $1.59B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of SUPN and 32 opened new positions — a net loss of 1 holder — while 101 trimmed existing stakes and 68 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $14.9M. The largest seller was Armistice Capital, cutting an estimated $31.8M.

  • 230 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2022, down from 235 in Q4 2021.
  • Funds reported $1.64B of Supernus Pharmaceuticals stock for Q1 2022, up 3.3% quarter-over-quarter.
  • 32 funds opened new Supernus Pharmaceuticals positions in Q1 2022 and 33 closed out, a net change of -1 holder.
  • The largest Supernus Pharmaceuticals buyer in Q1 2022 was Woodline Partners, an estimated $14.9M added.
  • The largest Supernus Pharmaceuticals seller in Q1 2022 was Armistice Capital, an estimated $31.8M sold.

Based on aggregated 13F filings for Q1 2022.